Cencora, Inc. $COR Shares Acquired by Fairtree Asset Management Pty Ltd

Fairtree Asset Management Pty Ltd lifted its stake in Cencora, Inc. (NYSE:COR) by 84.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,266 shares of the company’s stock after buying an additional 1,957 shares during the period. Fairtree Asset Management Pty Ltd’s holdings in Cencora were worth $1,333,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of COR. River Wealth Advisors LLC grew its holdings in shares of Cencora by 6.4% during the third quarter. River Wealth Advisors LLC now owns 42,905 shares of the company’s stock worth $13,409,000 after purchasing an additional 2,573 shares during the last quarter. Arete Wealth Advisors LLC lifted its holdings in shares of Cencora by 3.5% in the 3rd quarter. Arete Wealth Advisors LLC now owns 2,280 shares of the company’s stock valued at $719,000 after purchasing an additional 78 shares during the last quarter. Aviso Financial Inc. boosted its position in shares of Cencora by 9.9% in the 3rd quarter. Aviso Financial Inc. now owns 11,248 shares of the company’s stock valued at $3,515,000 after purchasing an additional 1,017 shares during the period. United Bank grew its stake in Cencora by 4.4% during the 3rd quarter. United Bank now owns 7,339 shares of the company’s stock worth $2,294,000 after buying an additional 307 shares during the last quarter. Finally, Rafferty Asset Management LLC grew its stake in Cencora by 18.0% during the 3rd quarter. Rafferty Asset Management LLC now owns 21,523 shares of the company’s stock worth $6,727,000 after buying an additional 3,282 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Up 1.4%

Shares of Cencora stock opened at $371.86 on Monday. Cencora, Inc. has a one year low of $248.59 and a one year high of $377.54. The company has a market cap of $72.34 billion, a P/E ratio of 44.69, a PEG ratio of 1.73 and a beta of 0.68. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92. The firm has a fifty day moving average of $351.72 and a two-hundred day moving average of $334.19.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. The business had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.73 earnings per share. On average, analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, February 13th. This represents a $2.40 annualized dividend and a yield of 0.6%. Cencora’s payout ratio is presently 28.85%.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the transaction, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 15,220 shares of company stock valued at $5,282,867. Corporate insiders own 0.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on COR. UBS Group boosted their price objective on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Mizuho lifted their price objective on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, TD Cowen upped their target price on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $399.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.